Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR‐497‐5p/mTOR
Open Access
- 11 November 2020
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 112 (1) , 275-286
Abstract
Chemoresistance is a major obstacle in non–small cell lung cancer (NSCLC) treatment. The pseudogene keratin 17 pseudogene 3 (KRT17P3) has been previously shown to be upregulated in lung cancer tissues of patients with cisplatin resistance. In the present study, RT‐qPCR was performed to evaluate KRT17P3 levels in plasma samples collected from 30 cisplatin‐resistant and 32 cisplatin‐sensitive patients. We found that the plasma level of KRT17P3 is upregulated in cisplatin‐resistant patients, and the increased expression of plasma KRT17P3 is associated with poor chemotherapy response. Functional studies demonstrated that KRT17P3 overexpression in cultured NSCLC cells increases cell viability and decreases apoptosis upon cisplatin treatment in vitro and in vivo, while KRT17P3 knockdown has the opposite effect. Mechanistically, bioinformatics analysis, RNA immunoprecipitation, and dual luciferase reporter assay indicated that KRT17P3 acts as a molecular sponge for miR‐497‐5p and relieves the binding of miR‐497‐5p to its target gene mTOR. Rescue experiments validated the functional interaction between KRT17P3, miR‐497‐5p, and mTOR. Taken together, our findings indicate that KRT17P3/miR‐497‐5p/mTOR regulates the chemosensitivity of NSCLC, suggesting a potential therapeutic target for cisplatin‐resistant NSCLC patients. KRT17P3 may be a potential peripheral blood marker of NSCLC patients resistant to cisplatin.Keywords
All Related Versions
Funding Information
- Nanjing Science and Technology Commission (201715059)
- Jiangsu Provincial Medical Youth Talent (QNRC2016126)
- National Natural Science Foundation of China (81572937, 81770082, 81772500)
This publication has 28 references indexed in Scilit:
- MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1Oncotarget, 2015
- Pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) as a novel plasma-based biomarker for hepatocellular carcinoma screeningTumor Biology, 2015
- MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1Oncotarget, 2015
- Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma ProgressionMolecular Cancer Therapeutics, 2014
- Long Noncoding RNAs Expression Patterns Associated with Chemo Response to Cisplatin Based Chemotherapy in Lung Squamous Cell Carcinoma PatientsPLOS ONE, 2014
- Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinomaCarcinogenesis, 2013
- A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?Cell, 2011
- Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteinsEuropean Journal of Pharmacology, 2008
- Overcoming cisplatin resistance by mTOR inhibitor in lung cancerMolecular Cancer, 2005
- Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycinEuropean Journal of Pharmacology: Molecular Pharmacology, 1993